Did Sperm and Egg Donors Unwittingly Contribute to NIH-Approved Stem Cells?
By Jocelyn Kaiser,
ScienceInsider
| 02. 07. 2013
A review of the 200 or so human embryonic stem cell (hESC) lines
approved by the National Institutes of Health (NIH) for federal funding has found a possible ethical problem: Some of the cells may have come from sperm or egg donors who didn't consent to having their cells used in research. University oversight committees should be aware that these cell lines may not meet widely accepted standards, the authors say.
In July 2009, following an order from President Barack Obama, NIH
issued guidelines laying out ethical standards that all hESC lines studied with NIH funding must meet. The cell lines must have been derived from surplus embryos donated by couples receiving fertility treatments, for example. But the guidelines
don't discuss the possibility that some embryos made have been created using donor eggs or sperm, even though 2005 National Academy of Sciences (NAS) guidelines call for consent from gamete donors. Research administrators at the Rockefeller University in New York City became concerned about this gap last year after a survey suggested that U.S. in vitro fertilization (IVF) clinics usually don't...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...